| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 |
| 03 Nov 2026 |
Form 4: Malzahn Craig, Chief Technology Officer
Received 27,777 shares as a grant or award |
| 03 Nov 2026 |
Form 4: Christmas Patrick J., Chief Strategy & Legal Officer
Received 34,722 shares as a grant or award |
| 03 Nov 2026 |
Form 4: Pakola Steve, Chief Medical Officer
Received 34,722 shares as a grant or award |
| 03 Nov 2026 |
Form 4: Chan Mitchell, Chief Financial Officer
Received 24,305 shares as a grant or award |
| 16 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 14, 2026, Kenneth T. Mills resigned from the board of directors (the “Board”) of REGENXBIO Inc. (the “Company”) effective October 21, 2026. Mr. Mills recently became chief executive officer of another company and intends to fo... |
| 13 Oct 2026 | SCHEDULE 13G |
| 23 Sep 2026 |
8-K: Entry into a Material Definitive Agreement
On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta Therapeutics ... |
| 03 Sep 2026 |
Form 4: Malzahn Craig, Chief Technology Officer
Gave up 234 shares to cover exercise price or tax ($2.18K) |
| 03 Sep 2026 |
Form 4: Chan Mitchell, Chief Financial Officer
Gave up 4,902 shares to cover exercise price or tax ($45.7K) |
| 27 Aug 2026 |
Form 4: Ciongoli Gregory Austin, Director
Received 15,432 shares as a grant or award · Granted 69,609 Stock Options (Right to buy) · Bought 49,196 shares ($450K) · 1 more |
| 27 Aug 2026 |
Form 3: Ciongoli Gregory Austin, Director
No securities owned |
| 25 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
ROCKVILLE, Md., August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of pot... |
| 24 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
ROCKVILLE, Md., August 24, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as ... |
| 06 Aug 2026 | 10-Q |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 |
| 04 Aug 2026 |
Form 4: Pakola Steve, Chief Medical Officer
Gave up 7,468 shares to cover exercise price or tax ($72.4K) |
| 04 Aug 2026 |
Form 4: Christmas Patrick J., Chief Strategy & Legal Officer
Gave up 4,699 shares to cover exercise price or tax ($45.5K) |
Loading...